 | Early-stage drug development plays a critical role in expanding therapeutic possibilities for patients globally, especially for conditions that are difficult to manage or treat. To address unmet patient needs and develop next generation drug products, pharmaceutical manufacturers are increasingly exploring novel molecules, like cannabinoids. This whitepaper explores the latest science-based benefits behind cannabinoids – with a focus on CBD – and new opportunities for innovation in the pharmaceutical space. It will then cover how DSM is supporting early-stage drug development in this groundbreaking field of research as a science led, co-innovation partner to the pharmaceutical industry. Inside:
Request Free! |
